‍

The ACIP recommendation has significantly expanded1*

‍
From risk-based to routine age-based From risk-based to routine age-based ‍
‍

~133 million
people are now eligible for protection from hepatitis B1,2

‍
‍

Nearly 
3 of 4 acute hepatitis B cases in 2022 occurred in people with no reported risk factors3

It may be difficult to predict who can contract hepatitis B4

‍

All eligible adults should be protected1*

checkmark

All eligible adults aged 19‑59 SHOULD receive hepatitis B vaccination

checkmark

Adults aged 60+ with risk factors SHOULD receive hepatitis B vaccination

checkmark

Adults aged 60+ without known risk factors MAY receive hepatitis B vaccination

Chronic hepatitis B can lead to serious consequences, including4,5†:

  • LIVER CANCER
  • CIRRHOSIS
  • LIVER TRANSPLANT
  • DEATH

Liver cancer is the second-leading cause of cancer deaths in the world6

54%

of liver cancer cases worldwide are due to hepatitis B7

On average in the US, there are 42,000 new liver cancer cases and 30,000 deaths each year; not all cases are hepatitis B–related.8

†For most people, HBV clears on its own. But for those who don’t clear the virus, it can cause liver cancer. From 2018–2022, there were an estimated 13,000–22,000 cases of acute hepatitis B annually; some may progress to chronic hepatitis B and potentially life-threatening consequences.1,4,9,10

HEPLISAV‑B does not treat liver diseases such as cirrhosis or liver cancer.11

‍

Hepatitis B has no cure10

‍

Although treatments are available, the best way to prevent it is through vaccination‡

‍

Your role is critical in achieving elimination

‍

Together with the World Health Organization (WHO) and the US Department of Health and Human Services (HHS), we can help eliminate hepatitis B by 203012

World Health Organization logo

WHO’s global hepatitis strategy, endorsed by all WHO member states, aims to reduce new hepatitis B infections by 90% and deaths by 65% by 2030.13

U.S. Department of Health and Human Services: Enhancing the health and well-being of all Americans

The Viral Hepatitis Elimination Plan provides a framework to control the viral hepatitis epidemic and eliminate viral hepatitis as a public health threat in the United States by 2030.12

‍

Effective vaccination strategies have led to disease elimination in the US14

‍
5 outlines of people with one filled in

4 out of 5 adults§

likely don’t have vaccine-induced immunity1,15

§Born before 1991.

‍
Hand in a stop motion

Stop hepatitis B

Help meet the WHO goal of elimination by 203013

‍

*As of April 2022, the ACIP recommends hepatitis B vaccination for all adults aged 19–59 and for adults aged ≥60 years with risk factors. Adults aged ≥60 years without risk factors may receive hepatitis B vaccination. Please refer to the hepatitis B vaccination guidelines noted in the MMWR publication for the specific risk factors for hepatitis B. This recommendation applies to adults who have not received a complete hepatitis B vaccine series in their lifetime.1

‡For most people, hepatitis B clears on its own. For those who don't clear the virus, the resulting health complications can be lifelong or even deadly. There is no way of definitively knowing who will clear the virus and who will not.1,4

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; HHS=Department of Health and Human Services; MMWR=Morbidity and Mortality Weekly Report; WHO=World Health Organization

Your Role Is Critical
‍
Dosing Efficiency
‍

This site uses cookies to improve your experience. By continuing to use this website you are agreeing to our Cookie Policy.

INDICATION AND IMPORTANT SAFETY INFORMATION + –

INDICATION
HEPLISAV‑B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV‑B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV‑B, including yeast.

IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV‑B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV‑B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV‑B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV‑B.

Hepatitis B has a long incubation period. HEPLISAV‑B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%‑39%), fatigue (11%‑17%), and headache (8%‑17%).

There are no clinical studies of HEPLISAV‑B in pregnant women. Available human data on HEPLISAV‑B administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

It is not known whether HEPLISAV‑B is excreted in human milk. Data are not available to assess the effects of HEPLISAV‑B on the breastfed infant or on milk production/excretion.

Vaccination with HEPLISAV‑B may not result in protection of all vaccine recipients.

ADDITIONAL IMPORTANT INFORMATION
HEPLISAV‑B does not treat liver diseases such as cirrhosis or liver cancer.11

Not all liver cancer is caused by the hepatitis B virus.16

Please see full Prescribing Information.

REFERENCES:

1. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. doi:10.15585/mmwr.mm7113a1 2. Data on file. Dynavax Technologies Corporation. Flow model for universal hepatitis B vaccination (version 4.5) assumptions. May 24, 2021. 3. Centers for Disease Control and Prevention. Availability of information on risk behaviors or exposures associated with reported cases of acute hepatitis B — United States, 2022. Last reviewed April 3, 2024. Accessed July 12, 2024. https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-b/figure-2.7.htm 4. Centers for Disease Control and Prevention. Clinical overview of hepatitis B. Last reviewed February 9, 2024. Accessed June 4, 2024. https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/ 5. Doshani M. Evidence to recommendations framework: should all HepB-unvaccinated adults receive hepatitis B vaccination? Presented to ACIP; September 29, 2021. 6. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598-1606. doi:10.1016/j.jhep.2022.08.021 7. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-943. 8. National Cancer Institute. Cancer stat facts: liver and intrahepatic bile duct cancer. Accessed July 15, 2024. https://seer.cancer.gov/statfacts/html/livibd.html 9. Centers for Disease Control and Prevention. Number of reported cases of acute Hepatitis B virus infection and estimated infections — United States, 2014–2021. Last reviewed August 7, 2023. Accessed May 29, 2024. https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-b/figure-2.1.htm 10. Centers for Disease Control and Prevention. Hepatitis B surveillance 2022. Last reviewed April 3, 2024. Accessed May 29, 2024. https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-b.htm 11. HEPLISAV‑B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2023. 12. U.S. Department of Health and Human Services. Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021–2025). 2020. Washington, DC. 13. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021 towards ending viral hepatitis. June 2016. 14. Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11(1526):1-15. doi:10.3389/fmicb.2020.01526 15. He WQ, Guo GN, Li C. The impact of hepatitis B vaccination in the United States, 1999–2018. Hepatology. 2022;75(6):1566-1578. doi:10.1002/hep.32265 16. National Cancer Institute. Liver cancer causes, risk factors, and prevention. Last updated May 15, 2024. Accessed July 15, 2024. https://www.cancer.gov/types/liver/what-is-liver-cancer/causes-risk-factors